BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and
InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient
cohorts of the INFORM-1 trial, an innovative Phase 1 study of two
direct-acting antiviral (DAA) compounds administered without interferon or
ribavirin for the treatment of patients chronically infected with the
hepatitis C virus (HCV).(i) The study, conducted by Roche as part of its
collaborations with InterMune and Pharmasset, combined the oral NS3 protease
inhibitor RG7227 (also known as ITMN-191) and the oral nucleoside analog
polymerase inhibitor RG7128.
